- ￥260 - 4690
- Solarbio
- 北京
- IN3500
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
NSC 781406
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1676893-24-5
- 规格：
100mg/50mg/25mg/10mg/5mg/1mg
| 规格： | 100mg | 产品价格： | ￥4690.0 |
|---|---|---|---|
| 规格： | 50mg | 产品价格： | ￥2928.0 |
| 规格： | 25mg | 产品价格： | ￥1828.0 |
| 规格： | 10mg | 产品价格： | ￥1018.0 |
| 规格： | 5mg | 产品价格： | ￥634.0 |
| 规格： | 1mg | 产品价格： | ￥260.0 |
| 基本信息 | |
| CAS | No.1676893-24-5 |
| 英文名称 | NSC 781406 |
| 分子式 | C29H27F2N5O5S2 |
| 分子量 | 627.68 |
| 溶解性 | Soluble in DMSO |
| 纯度 | ≥98% |
| 外观(性状) | Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| SMILES | COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C#CCN4CCN(CC4)S(=O)(=O)C)NS(=O)(=O)C5=C(C=C(C=C5)F)F |
| InChIKey | BBRINJUWZRLWKK-UHFFFAOYSA-N |
| InChI | InChI=1S/C29H27F2N5O5S2/c1-41-29-27(34-43(39，40)28-8-6-23(30)18-25(28)31)17-22(19-33-29)21-5-7-26-24(16-21)20(9-10-32-26)4-3-11-35-12-14-36(15-13-35)42(2，37)38/h5-10，16-19，34H，11-15H2，1-2H3 |
| PubChem CID | 127025628 |
| 靶点 | PI3K;mTOR |
| 通路 | PI3K/Akt/mTOR |
| 背景说明 | NSC781406是高效的 PI3K 和 mTOR 抑制剂。 |
| 生物活性 | NSC781406 is a highly potent PI3K and mTOR inhibitor with an IC50 of 2 nM for PI3Kα.[1] |
| In Vitro | NSC781406 demonstrates potent PI3K inhibition (PI3Kα IC50=2.0 nM) that translates into BEL-7404 cells proliferation inhibition (IC50=20 nM). NSC781406 displays reasonable liver microsome stability. NSC781406 demonstrates cytotoxic activities against leukemia， non-small cell， lung cancer， colon cancer， central nervous system cancer， melanoma， ovarian cancer， renal cancer， prostate cancer， and breast cancer. It is potent against 60 cancer cell lines with a mean GI50 value of 65 nM， and with a GI50 value less than 10 nM against four cancer cell lines[1]. |
| 细胞实验 | In the xenograft models， treatment with 30 mg/kg of NSC781406 results in statistically significant antitumor activity， with a mean reduction in relative tumor volume ratio of 52%. Sorafenib displays an inhibition ratio of 44% at 50 mg/kg. NSC781406 is well tolerated at 30 mg/kg， with no observed mortality or significant reduction of body weight[1]. |
| 细胞实验 | Cytotoxic effects are tested in the human lung adenocarcinoma cells A549， human colon cancer cells HCT-116， human breast cancer cells MDA-MB-231 and human hepatocellular carcinoma cells BEL-7404. These four tumor cells are diluted to a density of 40，000–50，000 cells/mL in logarithmic phase. After the cells are treated with compounds (NSC781406) for 72 h， MTT solution (5 mg/mL， 20 μL) is added another 4h at 37°C. IC50 values are determined by a nonlinear regression analysis[1]. |
| 动物实验 | Mice: NSC781406 is orally administered once a day 30 mg/kg for 14 consecutive days or with sorafenib at 50 mg/kg. The relative tumor volume to vehicle-treated control mice is monitored[1]. |
| 激酶实验 | IC50 values for inhibition of the PI3K is measured. PI-103 is used as the reference compound. The compounds (NSC781406) are tested in duplicate for 10 concentrations， 100 nM or 500 nM as the top concentration. All reagents are diluted in kinase buffer.Three-fold， ten-point serial compound (NSC781406) dilutions are performed in kinase buffer[1]. |
| 数据来源文献 | [1]. Chen Y， et al. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma. Bioorg Med Chem. 2016 Mar 1;24(5):957-66. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
IN3500 NSC 781406 抑制剂/拮抗剂/激动剂 索莱宝
￥260 - 4690
